Synbio Technologies

Executive Summary

Synbio Technologies is a well-established synthetic biology services company founded in 2005 and headquartered in Monmouth Junction, New Jersey. The company offers a comprehensive suite of DNA, RNA, and protein solutions, including gene synthesis, oligo synthesis, virus packaging, gene editing tools, antibody services, and protein expression. Its 'one-stop solution' model caters to academic researchers and biotech firms seeking high-quality biological molecules to accelerate discovery. Despite being a private company with limited public financial disclosures, Synbio Technologies has built a reputation over nearly two decades as a reliable partner in the rapidly growing synthetic biology market, which is projected to exceed $30 billion by 2030. The company's broad service portfolio positions it to capture demand across multiple applications, from basic research to therapeutic development. While the lack of recent funding or valuation data introduces some uncertainty, Synbio Technologies' longevity and comprehensive offerings suggest a stable operational base and potential for steady growth as the synthetic biology field expands.

Upcoming Catalysts (preview)

• Q4 2026Launch of Enhanced Gene Synthesis Platform with Faster Turnaround and Reduced Error Rates70% success
• H1 2027Strategic Partnership with a Mid-to-Large Pharmaceutical Company for CRISPR-Based Therapeutic Development Services50% success
• Q2 2027Expansion into New Markets via ISO Certification or GMP Compliance for Protein Production60% success